Product Description
Carmegliptin is a potent, long-acting, selective, orally bioavailable, pyrrolidinone-based inhibitor of dipeptidyl peptidase 4 (DPP-4), with hypoglycemic activity. Carmegliptin shows extensive tissue distribution and is excreted unchanged in the urine and bile. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Carmegliptin)
Mechanisms of Action: DPP4 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous, Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Hoffmann-La Roche
Company Location:
Company CEO: Severin Schwan
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Type 2 Diabetes
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2007-001257-25 |
2007-001257-25 | P2 |
Completed |
Type 2 Diabetes |
2008-04-28 |
2025-06-29 |
Treatments |
|
NCT00502710 |
BC20779 | P2 |
Completed |
Type 2 Diabetes |
2008-04-01 |
2019-03-21 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|